NCT06504056

Brief Summary

This study intends to retrospectively-prospectively enroll NVM patients from multiple centers to establish a natural population cohort of NVM patients. By collecting clinical data and biological samples from surgical patients, the investigators will construct a prognosis prediction system for NVM, optimize risk stratification, explore new strategies for the early prevention and treatment of NVM, and improve the efficiency of clinical treatment of NVM patients.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
52mo left

Started Oct 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress26%
Oct 2024Sep 2030

First Submitted

Initial submission to the registry

July 10, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 16, 2024

Completed
4 months until next milestone

Study Start

First participant enrolled

October 30, 2024

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

Expected
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2030

Last Updated

July 22, 2024

Status Verified

July 1, 2024

Enrollment Period

2.8 years

First QC Date

July 10, 2024

Last Update Submit

July 19, 2024

Conditions

Keywords

Isolated Noncompaction of the Ventricular MyocardiumPrognostic factors

Outcome Measures

Primary Outcomes (1)

  • Change in the incidence of mortality rate

    The survival status will be obtained from the medical records and phone calls to patients or their family members.

    At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3 year.

Study Arms (3)

Left ventricle group

The patients mainly had thickened myocardial wall with a thin, compacted epicardial layer and a thicker endocardial layer, and were diagnosed with LVNC.

Biological: Diagnosis of NVM

Right ventricle group

The patients mainly had thickened myocardial wall with a thin, compacted epicardial layer and a thicker endocardial layer, and were diagnosed with right NVM.

Biological: Diagnosis of NVM

Two sided ventricle group

The patients mainly had thickened myocardial wall with a thin, compacted epicardial layer and a thicker endocardial layer, and were diagnosed with right and left ventricle NVM.

Biological: Diagnosis of NVM

Interventions

The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.

Left ventricle group

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with NVM at all centers including The First Affiliated Hospital of Xi'an Jiaotong University.

You may qualify if:

  • The diagnosis of nvm was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
  • Patients or their families agreed to participate in the study and authorized informed consent.

You may not qualify if:

  • Incomplete clinical data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First Affiliated Hospital of Xi'an Jiantong University

Xi'an, Shaanxi, 710061, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

For the retrospectively enrolled patients, the investigators will collect their biological samples previously housed in the Biobank of The First Affiliated Hospital of Xi'an Jiaotong University. For the prospectively enrolled patients, the investigators will collect a variety of biological samples at admission, before discharge, 1st, 3rd, 6th, 9th month, 1st, 2nd, 3rd year after discharge, including blood, urine, feces, other types of body fluids (such as pericardial effusion), tissue samples from surgery and biopsy (such as pericardial effusion, myocardial tissue, tumors, blood clots, etc.), or samples that need to be disposed of as medical waste (blood clots, etc.), or the sample itself requires pathological examination to assist in diagnosis and treatment (e.g. endocardial muscle biopsy).

MeSH Terms

Conditions

Isolated Noncompaction of the Ventricular Myocardium

Condition Hierarchy (Ancestors)

Heart Defects, CongenitalCardiovascular AbnormalitiesCardiovascular DiseasesEndocardial FibroelastosisCardiomyopathiesHeart DiseasesAbnormalities, MultipleCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGenetic Diseases, X-LinkedGenetic Diseases, Inborn

Study Officials

  • Yang Yan

    First Affiliated Hospital Xi'an Jiaotong University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 10, 2024

First Posted

July 16, 2024

Study Start

October 30, 2024

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2030

Last Updated

July 22, 2024

Record last verified: 2024-07

Locations